Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering misjudges Claritin inventory

Executive Summary

Schering-Plough is reducing its fourth quarter earnings estimate by about $250 mil. (16-18 cents per share) because of "a more-rapid-than-anticipated decline in U.S. prescriptions for Claritin" following the OTC launch in December. Schering says it will not record any sales on shipments of Rx product to wholesalers until an actual prescription is dispensed...

You may also be interested in...

Schering Inventory Reductions Cause Drop In Intron, Temodar, Nasonex Sales

Schering-Plough's poor first quarter results reflect inventory buildup issues beyond Rx Claritin

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts